Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
278 participants
INTERVENTIONAL
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients
NCT02182557
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359
Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis
NCT04753034
The Effectiveness of Montelukast on Atopic Dermatitis in Koreans
NCT00903357
Does Treatment With Montelukast Improve Symptoms of Atopic Dermatitis in Children?
NCT02534467
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cetirizine Dry Syrup
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Giving informed consent
* Children who have 2 grades or more pruritus score.
* Children who require the treatment with external steroid preparation other than face and head.
* Children with a pruritus severity of 2.
* Mild or severe on the fist day of the treatment period.
Exclusion Criteria
* have a history of drug hypersensitivity
* are lactating or possibly pregnant female Children
* have a skin infection, or with zooparasite such as scabies and pediculosis
* cannot avoid the use of external steroid classified into strong, strongest or very strong
* have eczematous otitis externa with perforation in the eardrum
* have dermal ulcer, or profound heat burn or frostbite of the severity higher than the grade 2
* have asthma that requires the treatment with corticosteroid
* have pruritus only on face and head
* have inappropriate complication of dermal disorder that may influence on the evaluation of the study drug
* are undergoing specific desensitization therapy or immunomodulation therapy or phototherapy.
3 Years
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
104913
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.